PLRX PLIANT THERAPEUTICS, INC.

NEUTRAL Impact: 3/10 8-K
Horizon months Filed Mar 3, 2026 Processed 3mo ago SEC 0001746473-26-000024
8-K material event: Items 1.01
Final — all horizons settled through T+60d
PLRX ▼ -3.10% at T+60d
NEUTRAL call ✗ call lost -3.10% · α vs SPY -13.19% · entry $1.29 → $1.25
Currently $1.19 · -7.75% from $1.29 entry
Entry anchored
Mar 3, 03:59 PM ET
via Databento tick
T+1d
0.00%
call 0.00% · α +0.57%
$1.29
settled 3mo ago
T+5d
+3.10%
call +3.10% · α +4.43%
$1.33
settled 3mo ago
T+20d
+2.33%
call +2.33% · α +6.74%
$1.32
settled 2mo ago
T+60d
-3.10%
call -3.10% · α -13.19%
$1.25
settled 13d ago

Price Chart

Loading chart...

Executive Summary

Pliant Therapeutics extended the expiration date of its shareholder rights agreement from March 11, 2026 to March 11, 2027. The amendment is designed to prevent coercive takeover attempts by requiring potential acquirers to negotiate with the board, but was not made in response to any specific offer.

Actionable Insight

Monitor for any unsolicited takeover interest or activist activity, as the extended rights agreement gives the board more time to respond. The move suggests management wants to maintain control flexibility in a potentially volatile biotech M&A environment.

Key Facts

  • Pliant Therapeutics extended the expiration of its shareholder rights agreement by one year, from March 11, 2026 to March 11, 2027
  • The rights agreement allows the board to delay or prevent unsolicited takeover attempts
  • The amendment was not made in response to any specific takeover offer
  • The rights may still be redeemed, exchanged, or terminated earlier under existing terms

Financial Impact

No direct financial impact — this is a corporate governance measure

governancetakeover defenseshareholder rights

Risk Factors

  • Could deter potential acquirers if seen as entrenching management
  • May face shareholder opposition if perceived as anti-takeover without clear strategic rationale

Market Snapshot

Exchange
Nasdaq

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001746473-26-000024
Document: pliant-rightsagreementamen.htm0001746473-26-000024
Document: 0001746473-26-000024-index-headers.html0001746473-26-000024
Document: 0001746473-26-000024-index.html0001746473-26-000024
Document: 0001746473-26-000024.txt0001746473-26-000024
6 reports for PLRX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for PLRX — sortable, filterable
Type Now
May 11, 2026
29d ago
8-K
NEUTRAL ★ 4/10
$1.18 $1.18· 0.00%▼ −0.08%$1.19 (+0.85%)
May 11, 2026
29d ago
Press Release
BEARISH ★ 6/10
$1.18 $1.18· 0.00%▲ +0.08%$1.19 (−0.85%)
Apr 17, 2026
7w ago
8-K
MIXED ★ 6/10
$1.29 $1.21▼ −6.20%▼ −7.11%$1.19 (−7.75%)
Apr 7, 2026
9w ago
EFFECT
NEUTRAL ★ 4/10
$1.31 $1.30▼ −0.76%▼ −6.09%$1.19 (−9.16%)
Mar 11, 2026
12w ago
8-K
BULLISH ★ 7/10
$1.41 $1.33▼ −5.67%▼ −4.70%$1.19 (−15.60%)
Mar 3, 2026
14w ago
8-K
NEUTRAL ★ 3/10
$1.29 $1.33▲ +3.10%▲ +4.43%$1.19 (−7.75%)
Showing 6 of 6

US Market Status

Market Closed — Opens Thu (9h 37m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access